SANSAC Drug Patent Profile
✉ Email this page to a colleague
When do Sansac patents expire, and when can generic versions of Sansac launch?
Sansac is a drug marketed by Dow Pharm and is included in one NDA.
The generic ingredient in SANSAC is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sansac
A generic version of SANSAC was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for SANSAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 5,819 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SANSAC at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SANSAC
US Patents and Regulatory Information for SANSAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dow Pharm | SANSAC | erythromycin | SOLUTION;TOPICAL | 062522-001 | Jan 24, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |